189 related articles for article (PubMed ID: 30626487)
1. MUC16 suppresses human and murine innate immune responses.
Felder M; Kapur A; Rakhmilevich AL; Qu X; Sondel PM; Gillies SD; Connor J; Patankar MS
Gynecol Oncol; 2019 Mar; 152(3):618-628. PubMed ID: 30626487
[TBL] [Abstract][Full Text] [Related]
2. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.
Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS
Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172
[TBL] [Abstract][Full Text] [Related]
3. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
[TBL] [Abstract][Full Text] [Related]
4. Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.
Lakatos K; González G; Hoballah J; Brooker J; Jeong S; Evans C; Krauledat P; Hansen WP; Elias KM; Patankar M; Fülöp V; Konstantinopoulos PA; Cramer DW
J Ovarian Res; 2022 Feb; 15(1):28. PubMed ID: 35219339
[TBL] [Abstract][Full Text] [Related]
5. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
[TBL] [Abstract][Full Text] [Related]
8. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.
Thériault C; Pinard M; Comamala M; Migneault M; Beaudin J; Matte I; Boivin M; Piché A; Rancourt C
Gynecol Oncol; 2011 Jun; 121(3):434-43. PubMed ID: 21421261
[TBL] [Abstract][Full Text] [Related]
9. Virus-like particle vaccine displaying an external, membrane adjacent MUC16 epitope elicits ovarian cancer-reactive antibodies.
Tu HF; Wong M; Tseng SH; Ingavat N; Olczak P; Notarte KI; Hung CF; Roden RBS
J Ovarian Res; 2024 Jan; 17(1):19. PubMed ID: 38225646
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation.
Nemieboka B; Sharma SK; Rao TD; Edwards KJ; Yan S; Wang P; Ragupathi A; Piersigilli A; Spriggs DR; Lewis JS
Nucl Med Biol; 2020; 86-87():9-19. PubMed ID: 32403071
[TBL] [Abstract][Full Text] [Related]
11. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
12. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.
Patankar MS; Jing Y; Morrison JC; Belisle JA; Lattanzio FA; Deng Y; Wong NK; Morris HR; Dell A; Clark GF
Gynecol Oncol; 2005 Dec; 99(3):704-13. PubMed ID: 16126266
[TBL] [Abstract][Full Text] [Related]
13. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
Chen Y; Clark S; Wong T; Chen Y; Chen Y; Dennis MS; Luis E; Zhong F; Bheddah S; Koeppen H; Gogineni A; Ross S; Polakis P; Mallet W
Cancer Res; 2007 May; 67(10):4924-32. PubMed ID: 17510422
[TBL] [Abstract][Full Text] [Related]
14. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
15. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
Stasenko M; Smith E; Yeku O; Park KJ; Laster I; Lee K; Walderich S; Spriggs E; Rueda B; Weigelt B; Zamarin D; Rao TD; Spriggs DR
Sci Rep; 2021 Feb; 11(1):3718. PubMed ID: 33580170
[TBL] [Abstract][Full Text] [Related]
16. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
Front Immunol; 2021; 12():663379. PubMed ID: 33936101
[TBL] [Abstract][Full Text] [Related]
17. A novel monoclonal antibody to a defined peptide epitope in MUC16.
Marcos-Silva L; Ricardo S; Chen K; Blixt O; Arigi E; Pereira D; Høgdall E; Mandel U; Bennett EP; Vakhrushev SY; David L; Clausen H
Glycobiology; 2015 Nov; 25(11):1172-82. PubMed ID: 26201951
[TBL] [Abstract][Full Text] [Related]
18. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
Chekmasova AA; Rao TD; Nikhamin Y; Park KJ; Levine DA; Spriggs DR; Brentjens RJ
Clin Cancer Res; 2010 Jul; 16(14):3594-606. PubMed ID: 20628030
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
